Skip to content
Screener

Reported November 12, 2026 · After market close

Revenue$19.0MMiss by $1.4M
EPS-$0.05Miss by $0.03
Revenue estimate$20.3M
EPS estimate-$0.02
“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA. Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans. The number of unique prescribers writing for Emrosi® increased again during the third quarter and strong refill trends on top of new prescription growth are fueling momentum behind the brand and indicate high patient satisfaction with the product. Our recently expanded sales force and increasing formulary additions with national health plans are expected to facilitate further adoption and market penetration. Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”
Claude Maraoui

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$19.0M+7.6%
Gross profit$13.1M+10.2%
Operating income-$530.0K+65.3%
Net income-$1.3M+43.2%
EPS (diluted)-$0.05+44.4%

Balance sheet

See full
Cash & equivalents$22.3M-10.5%
Total debt$25.6M+1.3%
Total equity$32.2M+24.5%
Total assets$103.8M+21.9%

Cash flow

See full
Operating cash flow-$3.4M-44.2%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$127.57M-45.8%
Enterprise value$130.87M-44.5%
P/S1.8×-2.1×

Profitability

See full
Gross margin65.9%-4.2pp
Operating margin-2.9%—
Net margin-7.3%—

Returns & leverage

See full
Return on equity-17.6%—
Debt / equity0.8×-0.2×
Current ratio1.5×+0.1×

Segments

By product

See full
Emrosi$9.0M+84.4%
Qbrexza$5.6M-24.1%
Accutane$3.0M+9.2%
Foam Franchise Products Amzeeq Zilxi$942.0K-28.1%
Other Legacy$368.0K-47.5%

By segment

See full
Dermatological$19.0M—

FAQ

When did Journey Medical Corporation report Q3 2026 earnings?
Journey Medical Corporation (DERM) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Journey Medical Corporation's Q3 2026 revenue and EPS?
Journey Medical Corporation reported revenue of $19.0M and eps of $-0.05 for Q3 2026.
Did Journey Medical Corporation beat estimates in Q3 2026?
Revenue missed the consensus estimate of $20.3M by $1.4M. EPS missed the consensus estimate of $-0.02 by $0.03.
How did Journey Medical Corporation's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.6% from $17.6M a year earlier and eps grew 44.4% from $-0.09.
Where can I find Journey Medical Corporation's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-126209) and the 10-Q periodic report (0001104659-26-126285) directly on SEC EDGAR. The filing index links above go to sec.gov.